EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Nintedanib Accord for indications including Idiopathic Pulmonary Fibrosis, interstitial lung diseases, systemic sclerosis, and pulmonary fibr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Pulmonary Fibrosis
• Systemic Sclerosis

Drugs mentioned

• Nintedanib Accord (nintedanib)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases, Interstitial;Scleroderma, Systemic;Pulmonary Fibrosis. MAH: Accord Healthcare S.L.U.. Decision date: 29/08/2025